This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Exomphalos (Omphalocele)배꼽탈장증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q79.2 (exomphalos) | Special Copayment Reduction: V155
B. SynonymsOmphalocele, congenital abdominal wall hernia, Exomphalos, umbilical cord hernia
C. Adult onsetLikelihood of first onset in adulthood: very low — diagnosed immediately on prenatal ultrasound or by clinical findings at birth (abdominal wall defect, organ herniation); diagnosis being deferred until adulthood is extremely rare.
1. HistoryAbdominal wall malformation described since antiquity. Described by Ambroise Paré in the 16th century. 1948 Gross succeeded with primary closure. 1967 Schuster introduced staged repair with a silo. Prenatal ultrasound diagnosis from the 1970s.
2. CausesFailure of abdominal wall formation (failure of medial migration of the embryonic lateral folds). Sporadic. Associated anomalies and chromosomal abnormalities in about 50~70% (especially Beckwith-Wiedemann syndrome, trisomy 13/18). Increased risk with advanced maternal age.
3. GeneticsBeckwith-Wiedemann syndrome (BWS): 11p15.5 imprinting abnormality. Trisomy 13 (Patau), 18 (Edwards), 21 (Down) may be associated. Mostly sporadic. Recurrence risk about 1~3%.
4. General epidemiologyAbout 1 in 4,000~5,000 births. Associated anomalies in about 50~70%. Survival of isolated exomphalos without associated anomalies about 90%.
5. PathophysiologyFailure of return to the abdominal cavity after physiologic bowel herniation at 6~10 weeks of gestation, or defective medialization of the embryonic lateral folds → formation of a hernia sac covered by peritoneum and amnion at the umbilicus.
6. SymptomsHernia sac covered by peritoneum and amnion at the umbilicus (abdominal wall defect). Bowel exposed if the sac ruptures. Symptoms of associated heart malformations and chromosomal abnormalities. Gigantism (BWS). Giant exomphalos (liver herniation): difficult reduction into the abdominal cavity.
7. SignsPrenatal: abdominal wall defect at the umbilical cord insertion and protrusion of covered organs on ultrasound. Elevated MSAFP. After birth: hernia sac covered by peritoneum and amnion (centered on the umbilicus), with the umbilical cord inserting into the hernia sac.
8. ScreeningPrenatal ultrasound (NT scan at 11~14 weeks of gestation or anomaly scan at 18~22 weeks). Elevated MSAFP. Prenatal genetic testing (exclusion of trisomies, confirmation of BWS).
9. DiagnosisPrenatal ultrasound and MRI, genetic testing. After birth: confirmed by clinical findings (covered hernia sac). Differentiation from gastroschisis: presence of a covering sac, location (umbilicus vs. right of the umbilicus).
10. TreatmentSmall: primary closure. Giant (liver herniation): staged repair with a silo, or staged closure after epithelialization using topical agents. Treatment of associated anomalies. Management of hypoglycemia (BWS).
11. PrognosisIsolated: survival about 90%. With associated anomalies (cardiac, chromosomal): poor. Giant exomphalos: long-term complications such as pulmonary hypoplasia, gastroesophageal reflux, growth delay. Long-term tumor surveillance needed in BWS.
12. PreventionAfter prenatal diagnosis, planned delivery at a specialized tertiary medical institution. Prenatal diagnosis of associated genetic abnormalities. Folic acid intake (possible role in preventing abdominal wall defects in general). Regular surveillance of BWS patients.
13. ReferencesLedbetter DJ (2006) abdominal wall defects review … and 9 other papers

1. History

Exomphalos (omphalocele) is a congenital malformation that has been known since long ago in human history. Ancient Egyptian and Greek medical literature already contains records of children born with exposed viscera, and such malformations were mostly regarded as fatal. In the 16th century, the eminent French surgeon Ambroise Paré first described this malformation systematically and approached it from the perspective of teratology. In the 19th century, anatomists began to describe the pathology of this malformation in more detail, but the history of surgical treatment began in earnest only in the 20th century.

The most important turning point in the history of surgical treatment was in 1948, when Robert Gross of Boston Children's Hospital in the United States successfully performed primary closure. However, because reduction into the abdominal cavity and primary closure are often technically impossible in giant exomphalos, in 1967 Schuster introduced a method of reducing the herniated organs into the abdominal cavity in stages using a silo procedure with Silastic material, opening a new horizon in the treatment of giant exomphalos. Various materials and techniques have since developed, and today staged silo repair is established as the standard treatment.

The history of prenatal diagnosis began with the introduction of ultrasound technology in the 1970s. After Shalev et al. first diagnosed exomphalos by prenatal ultrasound in 1972, advances in ultrasound technology made it possible to detect exomphalos even on the fetal nuchal translucency (NT) scan at 11~14 weeks of gestation. Thanks to prenatal diagnosis, treatment plans can be established at specialized tertiary hospitals before delivery, and delivery can take place with pediatric surgery, neonatology, and medical genetics teams prepared, greatly improving treatment outcomes. In Korea as well, early diagnosis of exomphalos by prenatal ultrasound is standardized, and medical cost support is provided under rare disease Special Copayment Reduction (V155).

2. Causes

The cause of exomphalos lies in abnormalities in the process of fetal abdominal wall formation. In normal development, physiological midgut herniation occurs at around 5~6 weeks of gestation, with the bowel moving out into the umbilical cord and returning to the abdominal cavity at 10~12 weeks of gestation. At the same time, the embryo's lateral body folds in four directions fuse medially to form the abdominal wall. Exomphalos results when this return process fails or medial migration of the lateral folds is incomplete, so that the abdominal wall around the umbilical cord insertion does not form properly. That the herniated organs are enclosed in a two-layer covering membrane (sac) of peritoneum and amnion is the key point of differentiation from gastroschisis.

Associated anomalies or genetic abnormalities are present in about 50~70% of exomphalos. The most frequently associated genetic syndrome is Beckwith-Wiedemann syndrome (BWS), characterized by macroglossia, overgrowth, exomphalos, and neonatal hypoglycemia. Associated chromosomal abnormalities may include trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), trisomy 21 (Down syndrome), and trisomy X, in which case the prognosis is very poor. Congenital heart malformations are present in about 30~50% of patients with exomphalos and have an important effect on prognosis. Environmental risk factors such as smoking in early pregnancy, use of SSRIs (selective serotonin reuptake inhibitors) during pregnancy, advanced maternal age, and obesity have been reported to be associated in some studies, but a clear causal relationship has not been established.

3. Genetics

The genetics of exomphalos are heterogeneous, and it mostly occurs sporadically. The recurrence risk in siblings is about 1~3%, higher than in the general population but low in absolute terms. Familial occurrence is rare, and in such cases it sometimes suggests multifactorial inheritance or autosomal dominant inheritance. The genetic syndrome most strongly associated with exomphalos is Beckwith-Wiedemann syndrome (BWS). BWS is caused by abnormalities of the parental imprinting-related gene region (IGF2/H19 and KCNQ1OT1/CDKN1C) located on the short arm of chromosome 11 (11p15.5).

The molecular mechanisms of BWS are diverse: ① loss of IGF2 paternal imprinting (hypermethylation): about 50%, ② CDKN1C variants (maternally inherited): about 5~10%, ③ 11p15 paternal uniparental disomy (UPD): about 20%, ④ other methylation abnormalities: about 5%. Exomphalos occurs in about 10~20% of BWS patients, and conversely BWS is diagnosed in about 10~15% of patients with exomphalos. In addition to exomphalos, BWS is characterized by macroglossia, hemihypertrophy, neonatal hypoglycemia, and an increased risk of pediatric tumors such as Wilms tumor, hepatoblastoma, and neuroblastoma. Therefore, long-term surveillance for pediatric tumors is essential in exomphalos patients diagnosed with BWS.

To exclude chromosomal abnormalities, prenatal or postnatal chromosomal karyotyping and CMA are performed. Exomphalos occurs frequently in trisomy 13 and 18, and when these chromosomal abnormalities are present the prognosis is extremely poor, so ethical discussion about the appropriateness of aggressive treatment is needed. Whole exome sequencing (WES) can be used to identify the etiology in exomphalos patients associated with other genetic syndromes. In Korea as well, chromosomal testing and BWS molecular testing (11p15 methylation analysis, IGF2 imprinting testing) are performed in patients with exomphalos.

4. General epidemiology

Exomphalos, together with gastroschisis, is the most common type of abdominal wall defect, occurring at a frequency of about 1 in 4,000~5,000 births. About 10,000~20,000 newborns are affected annually worldwide. In US CDC statistics, exomphalos is reported at a frequency of about 1/4,200 births, with some variation by country and region. Recently, with the spread of prenatal ultrasound diagnosis, the actual frequency including stillbirths is being determined more accurately than in the past.

Associated anomalies and genetic abnormalities are found in about 50~70% of patients with exomphalos, much higher than the frequency of associated anomalies in gastroschisis (about 10~15%). Among associated anomalies, congenital heart malformations are the most common at about 30~50%, followed by genitourinary malformations, neural tube defects, and musculoskeletal malformations. Chromosomal abnormalities are present in about 30~50% of all exomphalos. Giant omphalocele: a defect size of 5cm or more or herniation of the liver, accounting for about 25~30% of the total. In giant exomphalos, reduction into the abdominal cavity is difficult and pulmonary hypoplasia may be present, so the prognosis is worse.

As a risk factor, increased frequency with advanced maternal age (35 years or older) has been reported, which is associated with the frequency of chromosomal abnormalities. In contrast, gastroschisis is more frequent in young mothers, so the epidemiologic features of the two diseases contrast. In Korea, exomphalos is included in rare disease Special Copayment Reduction (V155), and the domestic incidence is estimated to be similar to that in Western countries. Accurate domestic prevalence and incidence data can be determined through analysis of health insurance claims data or congenital anomaly registry programs.

5. Pathophysiology

The pathophysiology of exomphalos is an abnormality in the process of fetal abdominal wall formation. In normal development, physiological midgut herniation occurs at 5~6 weeks of gestation, with the rapidly growing midgut herniating into the umbilical cord to avoid the cramped abdominal cavity. At 10~12 weeks of gestation, when the abdominal cavity has grown sufficiently, the herniated bowel returns to the abdominal cavity, and the four lateral folds of the embryo (cranial, caudal, left lateral, right lateral folds) fuse medially to complete the abdominal wall. Exomphalos results when this return process fails or medial fusion of the lateral folds is incomplete, so that the abdominal wall around the umbilical cord insertion does not close properly.

Abdominal organs protrude externally through the defect but remain covered by a hernia sac composed of peritoneum and amnion. This covering membrane has a double structure of inner peritoneum and outer amnion, and the umbilical cord itself inserts at the apex of the hernia sac. The hernia sac may rupture spontaneously after birth or during delivery, and when the sac ruptures the organs are directly exposed. The hernia sac may contain the small intestine, large intestine, stomach, liver, and spleen, and reduction into the abdominal cavity is very difficult especially in giant omphalocele with liver herniation.

In giant exomphalos, pulmonary hypoplasia may occur because abdominal organs including the liver compress the thoracic cavity for a long period or the abdominal space does not develop, which causes respiratory complications similar to those in CDH. When the abdominal cavity is small and the volume of organs to be reduced is large, intra-abdominal pressure rises after primary reduction, and abdominal compartment syndrome may develop. In this case, bowel ischemia, lower limb venous congestion, worsening respiratory function, and renal failure may occur, so staged repair is needed. In BWS, IGF2 overexpression due to the 11p15 imprinting abnormality causes overgrowth, resulting not only in exomphalos but also in enlargement of the liver, kidneys, and adrenal glands and a predisposition to tumors.

6. Symptoms

Exomphalos is a clinically obvious malformation that can be diagnosed immediately at birth. The main finding observed immediately after birth is protrusion of a hernia sac enclosed in a peritoneal-amniotic covering membrane at the umbilical cord insertion. The size of the hernia sac varies from small (2~3cm in diameter, containing only bowel) to giant (10cm or more in diameter, containing liver). When the hernia sac is intact and unruptured, the sac membrane is characteristically transparent after birth, so the internal organs are visible. In small exomphalos, the sac contains only bowel and reduction into the abdominal cavity is possible, so primary closure is easy.

Giant omphalocele is when the defect size is 5cm or more or the liver is contained within the hernia sac; because the abdominal cavity has not developed sufficiently, primary reduction is impossible, and respiratory failure, hypothermia, fluid loss, and infection may occur. When the hernia sac ruptures, the organs are directly exposed, creating an emergency similar to gastroschisis. When associated heart malformations are present, cyanosis, dyspnea, and symptoms of heart failure additionally appear. When associated with Beckwith-Wiedemann syndrome (BWS), characteristic BWS findings are present, such as macroglossia (the tongue protruding larger than the oral cavity), generalized overgrowth (weight and height markedly greater than peers), neonatal hypoglycemia (especially severe within 48~72 hours after birth), hemihypertrophy, and ear creases/pits. In trisomy 18 or trisomy 13, exomphalos occurs together with severe systemic malformations, and survival is extremely short.

7. Signs

On prenatal ultrasound, exomphalos can be detected even on the NT scan at 11~14 weeks of gestation, but at this stage differentiation from physiologic bowel herniation is needed. After 12 weeks of gestation, identification of a hernia sac at the umbilical cord insertion together with the finding of umbilical vessels inserting at the apex of the hernia sac is specific for exomphalos. On the anomaly scan at 18~22 weeks of gestation, a hernia sac with a peritoneal-amniotic covering membrane is clearly observed at the umbilical cord insertion. The herniated organs (bowel, liver, spleen, etc.) are identified within the sac on ultrasound. Maternal serum alpha-fetoprotein (MSAFP) may be elevated in exomphalos, but its specificity is low.

The clinical sign after birth is a hernia sac covered by peritoneum and amnion at the umbilical cord insertion. The characteristic finding of the umbilical cord inserting at the apex of the hernia sac distinguishes it from gastroschisis. In gastroschisis, there is no covering membrane, the defect is to the right of the umbilicus, and the bowel is directly exposed. When the hernia sac has ruptured, clinical differentiation becomes more difficult, but it can be differentiated by identifying sac remnants (ruptured membrane) or by the location of the defect (umbilical center vs. right side). Echocardiography is essential to evaluate associated congenital heart malformations and is performed before abdominal repair surgery if possible. Blood glucose monitoring begins immediately after birth when BWS is suspected.

8. Screening

Prenatal screening for exomphalos is carried out through standard prenatal ultrasound examinations of pregnant women. Large, obvious exomphalos may be detected on the NT (nuchal translucency) scan at 11~14 weeks of gestation, but at this stage small exomphalos may be difficult to distinguish from physiologic bowel herniation. Most exomphalos is detected on the anomaly scan at 18~22 weeks of gestation. When exomphalos is identified on prenatal ultrasound, the patient is immediately referred to a maternal-fetal medicine (MFM) team, and detailed fetal ultrasound, fetal echocardiography, fetal MRI (evaluation of abdominal space and lung volume), and genetic testing are performed.

Prenatal genetic testing includes chromosomal karyotyping, CMA (evaluation of trisomies, microdeletions, duplications), and BWS molecular testing (11p15 methylation analysis). When ultrasound findings suggest trisomy 13 or 18 (multiple associated anomalies), the karyotype is rapidly confirmed by CVS (11~14 weeks) or amniocentesis (15~20 weeks). When maternal serum alpha-fetoprotein (MSAFP) is elevated in the second trimester, abdominal wall defects including exomphalos are suspected and detailed ultrasound is performed. Postnatal screening is done immediately on clinical examination; because the abdominal malformation is obvious, diagnosis is made by visual confirmation without separate screening tests.

9. Diagnosis

Exomphalos is diagnosed by prenatal ultrasound or by clinical findings after birth. After birth, the clinical diagnosis is confirmed when a hernia sac covered by a peritoneal-amniotic membrane is observed at the umbilical cord insertion. The most important differential diagnosis is gastroschisis. Points of differentiation between exomphalos and gastroschisis: ① defect location: exomphalos at the umbilical center, gastroschisis to the right of the umbilicus; ② presence of a covering membrane: exomphalos has a peritoneal-amniotic covering membrane, gastroschisis does not; ③ herniated organs: exomphalos may also include the liver and spleen, gastroschisis mainly bowel only; ④ umbilical cord insertion: exomphalos inserts at the apex of the hernia sac, gastroschisis in the normal position to the left of the defect.

Additional postnatal tests include echocardiography (evaluation of associated heart malformations), renal ultrasound (associated genitourinary malformations), blood glucose monitoring (BWS hypoglycemia), chromosomal karyotyping and CMA, and BWS molecular testing. For abdominal and surgical planning, abdominal CT or MRI is performed to evaluate the abdominal space, the composition of herniated organs, and lung volume. An assessment of the newborn's general condition (blood gas analysis, biochemistry panel, blood glucose, electrolytes) is performed to establish a preoperative stabilization plan. A multidisciplinary collaboration system of pediatric surgery, neonatology, cardiac surgery, medical genetics, and pediatric endocrinology (management of BWS hypoglycemia) is established.

10. Treatment

Treatment of exomphalos is individualized according to the defect size, the type of herniated organs, associated anomalies, and the newborn's general condition. The core of treatment is ① protecting the hernia sac or exposed organs, ② staged reduction into the abdominal cavity, ③ correction of the abdominal wall defect, and ④ treatment of associated anomalies. The timing of surgery is determined by the newborn's condition, the defect size, and the urgency of associated anomalies.

In small exomphalos (defect < 5cm, no liver herniation), the standard treatment is reduction of the herniated organs into the abdominal cavity and primary closure of the abdominal wall defect (primary fascial closure). If intra-abdominal pressure rises excessively during primary closure, abdominal compartment syndrome may develop, so monitoring of intravesical or intra-abdominal pressure is needed. When primary closure is possible, surgery is usually performed within 24~72 hours after birth.

In giant omphalocele (defect ≥ 5cm or liver herniation), primary closure is impossible, so staged repair is needed. There are two main approaches. ① Staged silo repair: while preserving the herniated organs within the hernia sac or an artificial silo, they are reduced into the abdominal cavity a little each day, and after complete reduction over days to weeks, the abdominal wall is repaired. ② Epithelialization using topical agents (topical agent/epithelization): a method in which topical agents such as silver-containing dressings, polyvinylidene film, or methylene blue are applied to the hernia sac to induce epithelialization of the sac membrane, and after the sac membrane becomes skin-covered over weeks to months, staged repair is performed. This method is used when early surgery is risky because of pulmonary hypoplasia or severe heart malformations.

Treatment of associated anomalies is also important. When congenital heart malformations are present, the priority and timing of abdominal wall repair surgery and cardiac surgery are determined through multidisciplinary conferences. BWS-related neonatal hypoglycemia is corrected by immediate intravenous glucose administration, and in severe cases diazoxide or a growth hormone inhibitor (octreotide) is considered. In BWS patients, abdominal ultrasound (at 3~4-month intervals) and AFP measurement are performed regularly until age 8 for surveillance of pediatric tumors (Wilms tumor, hepatoblastoma, etc.).

11. Prognosis

The prognosis of exomphalos differs greatly depending on the defect size, the presence of associated anomalies, and the presence of chromosomal abnormalities. Survival in isolated small exomphalos without associated anomalies is excellent at about 90% or more. In contrast, when associated heart malformations or chromosomal abnormalities are present, survival is markedly reduced. When accompanied by trisomy 18 (Edwards syndrome) or trisomy 13 (Patau syndrome), survival is extremely low.

In giant exomphalos with pulmonary hypoplasia, the risk of neonatal death increases, as in CDH. Survival in giant exomphalos with liver herniation is reported to be about 70~80%. Long-term postoperative complications include ① gastroesophageal reflux (GERD): common because of increased intra-abdominal pressure after reduction, sometimes requiring medication or antireflux surgery; ② bowel obstruction and stricture: bowel obstruction due to postoperative adhesions may occur; ③ recurrence of abdominal wall hernia: abdominal wall hernia may recur at the patch repair site, so long-term follow-up is needed; ④ reduced lung function: when giant exomphalos is accompanied by pulmonary hypoplasia, chronically reduced lung function may persist; ⑤ BWS-related tumors: in patients with BWS, there is a risk of Wilms tumor, hepatoblastoma, neuroblastoma, etc. developing before age 8, so regular abdominal ultrasound surveillance is essential.

12. Prevention

There is no established method to prevent the occurrence of exomphalos itself. However, prenatal diagnosis and planned delivery at a specialized tertiary medical institution are the most important strategies for improving neonatal survival and prognosis. When exomphalos is diagnosed on prenatal ultrasound, the patient should be immediately referred to a tertiary medical institution equipped with maternal-fetal medicine (MFM), pediatric surgery, and neonatology to establish multidisciplinary counseling and a treatment plan before delivery.

Folic acid intake before and in early pregnancy is known to reduce the risk of several congenital malformations, including neural tube defects, and some protective effect against abdominal wall defects has also been reported, but the evidence is not yet established. General pregnancy health rules of avoiding smoking, alcohol, and unnecessary medications during pregnancy are followed. Because the risk of associated chromosomal abnormalities increases with advanced maternal age, in pregnant women aged 35 or older, chromosomal abnormalities are detected early through prenatal genetic testing (noninvasive prenatal testing, NIPT, or invasive testing), and sufficient genetic counseling is provided.

When associated genetic abnormalities are identified (especially BWS, trisomies, etc.), genetic counseling is provided on the recurrence risk and prevention strategies according to the mode of inheritance of the genetic abnormality. In BWS families, the recurrence risk differs according to the characteristics of the 11p15 imprinting abnormality, and preimplantation genetic testing (PGT) is possible in some cases. After the birth of a child with exomphalos, intensive prenatal ultrasound surveillance and genetic counseling are recommended in the next pregnancy. In exomphalos survivors diagnosed with BWS, tumor development should be monitored early during childhood with regular abdominal ultrasound and AFP measurement.

13. References

  1. Ledbetter DJ. Gastroschisis and omphalocele. Surg Clin North Am. 2006;86(2):249-260. DOI: 10.1016/j.suc.2005.12.003. PMID: 16580930.

  2. Stoll C, Alembik Y, Dott B, Roth MP. Associated malformations in patients with omphalocele. Eur J Med Genet. 2008;51(4):326-334. DOI: 10.1016/j.ejmg.2008.02.011. PMID: 18395505.

  3. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol. 2005;8(3):287-304. DOI: 10.1007/s10024-005-1154-9. PMID: 16010496.

  4. Baerg J, Kaban G, Tonita J, Pahwa P, Reid D. Gastroschisis: a sixteen-year review. J Pediatr Surg. 2003;38(5):771-774. DOI: 10.1016/jpsu.2003.50179. PMID: 12720193.

  5. Marshall J, Salemi JL, Tanner JP, et al. Prevalence, correlates, and outcomes of omphalocele in the United States, 1995-2005. Obstet Gynecol. 2015;126(2):284-293. DOI: 10.1097/AOG.0000000000000920. PMID: 26241420.

  6. Groner JI, Teich S. Management of large omphalocele with a spring-loaded silo device. J Pediatr Surg. 2008;43(11):1961-1964. DOI: 10.1016/j.jpedsurg.2008.05.039. PMID: 18970924.

  7. Christison-Lagay ER, Kelleher CM, Langer JC. Neonatal abdominal wall defects. Semin Fetal Neonatal Med. 2011;16(3):164-172. DOI: 10.1016/j.siny.2011.02.009. PMID: 21454143.

  8. Brisse HJ, Galmiche-Rolland L. Beckwith-Wiedemann syndrome: overview of tumor risk factors and surveillance guidelines. Pediatr Blood Cancer. 2019;66(10):e27907. DOI: 10.1002/pbc.27907. PMID: 31265776.

  9. Islam S. Abdominal wall defects. Pediatr Clin North Am. 2014;61(5):1085-1101. DOI: 10.1016/j.pcl.2014.06.003. PMID: 25213105.

  10. Lap CCMM, Brizot ML, Pistorius LR, et al. Outcome of isolated fetal omphalocele: a systematic review and meta-analysis. Eur J Pediatr Surg. 2016;26(5):393-401. DOI: 10.1055/s-0036-1584153. PMID: 27303931.